Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.
about
Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!The ubiquitous mineralocorticoid receptor: clinical implicationsSodium-retaining effect of insulin in diabetesMyeloid mineralocorticoid receptor activation contributes to progressive kidney disease.Clinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trials.Moderate inappropriately high aldosterone/NaCl constellation in mice: cardiovascular effects and the role of cardiovascular epidermal growth factor receptor.Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations.Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628.Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?Aldosterone and the risk of hypertensionA critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension.The possibility of resistant hypertension during the treatment of hypertensive patients.The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists.Context-dependent mechanisms modulating aldosterone signaling in the kidney.Roles of oxidative stress and the mineralocorticoid receptor in cardiac pathology in a rat model of metabolic syndrome.Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension.Association of Mineralocorticoid Receptor Polymorphism I180V With Left Ventricular Hypertrophy in Resistant Hypertension.
P2860
Q26776149-8C31339B-8F74-442A-9700-DF66DD1B420BQ26861721-EB777357-B177-48AF-8A24-2DBD729AA718Q27015001-2A0665A2-4E81-43DE-8EED-4CB83BE0951AQ34259981-AC590F71-DB38-4F46-8A81-1207D9DFCA57Q34671912-5BDD899F-1FC9-4BB8-8D84-CC2C8B09D74EQ34675520-8A9F6121-5412-4A74-AD3C-DCA428AC2B33Q35231679-5A4018C1-6059-4325-AC6D-8B4B19A376CDQ35877719-0CA8D1CE-6913-4BD6-B6EB-93F7F85D8CA3Q36437145-57516BA3-31A1-4E0C-AE55-AE48A95E2225Q36747846-6E5FB9D3-2820-4157-8715-B4F25A6FA083Q38108677-0319E3C6-0EFF-4054-BC6E-97AD1D7365F5Q38136479-9A7E09C5-1119-42A3-B627-4CE53D6B8762Q38374536-CE57A5F7-0A71-4805-AE57-898E83B6FB04Q38383249-A81CC070-79F9-4C04-B58E-FF3DCB734224Q38723454-7B9C70AF-831B-4A9D-A726-D10CF0008356Q43188322-A437A221-81F5-471C-B1EA-9EF9E2DECB2BQ47120314-DA8A701D-5309-4484-9E93-5F9B8162FE2DQ48115107-8303AAB5-4D50-4063-8E32-AE7BE6102420Q53476197-AC615C3D-7BE1-4C1C-BA62-9CBA0E447B51
P2860
Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Mineralocorticoid receptor-ass ...... ce for resistant hypertension.
@en
Mineralocorticoid receptor-ass ...... ce for resistant hypertension.
@nl
type
label
Mineralocorticoid receptor-ass ...... ce for resistant hypertension.
@en
Mineralocorticoid receptor-ass ...... ce for resistant hypertension.
@nl
prefLabel
Mineralocorticoid receptor-ass ...... ce for resistant hypertension.
@en
Mineralocorticoid receptor-ass ...... ce for resistant hypertension.
@nl
P2860
P356
P1476
Mineralocorticoid receptor-ass ...... ce for resistant hypertension.
@en
P2093
Hiroshi Itoh
Hirotaka Shibata
P2860
P304
P356
10.1038/AJH.2011.245
P577
2012-01-19T00:00:00Z